tbuckley/cabot-search huggingface dataset:
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
Authors: Shaji K Kumar, Simon J Harrison, Michele Cavo, Javier de la Rubia, Rakesh Popat, Cristina Gasparetto, Vania Hungria, Hans Salwender, Kenshi Suzuki, Inho Kim, Elizabeth A Punnoose, Wan-Jen Hong, Kevin J Freise, Xiaoqing Yang, Anjla Sood, Muhammad Jalaluddin, Jeremy A Ross, James E Ward, Paulo C Maciag, Philippe Moreau
Journal: The Lancet Oncology (2020)
Dietary simple sugars alter microbial ecology in the gut and promote colitis in mice
Authors: Shahanshah Khan, Sumyya Waliullah, Victoria Godfrey, Md Abdul Wadud Khan, Rajalaksmy A. Ramachandran, Brandi L. Cantarel, Cassie Behrendt, Lan Peng, Lora V. Hooper, Hasan Zaki
Journal: Science Translational Medicine (2020)

High-sugar diet promotes the growth of mucolytic bacteria, leading to reduction of the mucus layer and predisposition to colitis in mice.
Interim Analysis from a Prospective Multicenter Study of Next-Generation Sequencing Minimal Residual Disease Assessment and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma
Authors: Anita Kumar, Jason Westin, Stephen J Schuster, Grzegorz S. Nowakowski, Izidore S. Lossos, Connie Lee Batlevi, Philip Caron, Pamela Drullinsky, John Gerecitano, Audrey Hamilton, Paul A. Hamlin, Steven M. Horwitz, Allison P. Jacob, Erel Joffe, Ashlee Joseph, Gottfried R. von Keudell, Leana Laraque, Oscar B Lahoud, Matthew J Matasar, Craig H. Moskowitz, Chelsea D Mullins, Ariela Noy, Colette Owens, Maria Lia Palomba, Carol S. Portlock, Ildefonso Rodriguez-Rivera, Gilles Salles, Venkatraman Seshan, David J. Straus, Shreya Vemuri, Anas Younes, Andrew D Zelenetz
Journal: Blood (2020)
Specialty Pharmacy and Physician Partnership Optimizes Clinical Pathway Adherence in Myelofibrosis (MF): Initial Analysis of a Quality Improvement Initiative
Authors: Aleksander L. Chojecki, Kristyn Y. DiSogra, Justin Arnall, Nicole Cowgill, Srinivasa Reddy Sanikommu, Nilay A. Shah, Charles H. Packman, Brittany K. Ragon, Thomas G. Knight, Jing Ai, Belinda R Avalos, Edward A Copelan, Michael R. Grunwald
Journal: Blood (2020)
FRI0132 Decreased serum dnase 1 activity levels in sle patients with active disease
Authors: I Gunnarsson, F Guo-Zhong, HG Mannherz, M Napirei, A Gültekin, J Frostegård
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> DNASE 1 (deoxyribonuclease 1; EC 3.1.21.1) deficient mice have been shown to develop classical symptoms of Systemic Lupus Erythematosus (SLE) with anti-nuclear antibodies in the circulation. Low serum DNASE 1 activity has been reported in patients with SLE. <h3>Objectives</h3> The aim of this study was to investigate serum DNASE 1 activity in SLE patients in relation to disease activity. In addition, the relationship between the DNASE 1 activity and renal involvement was analysed. <h3>Methods</h3> Serum samples from fifty patients with SLE (ACR criteria), 39 females and 11 males, mean age 44, were analysed for DNASE 1 activity by the single radial enzyme-diffusion method (SRED) (Nadano <i>et al</i>., 1993). All sera were analysed on three separate occasions and the mean value (pg/ml) from the three experiments was used. Anti-dsDNA antibodies were detected by indirect IFL. SLE disease activity was assessed according to the Systemic Lupus Activity Measure (SLAM). A SLAM score of 7 or above was considered as high. Thirty (60%) had high disease activity (SLE/active), the other 20 patients (SLAM &lt;7) were classified as SLE/inactive. Twenty-six (52%) of the 50 SLE patients had glomerulonephritis, in all cases confirmed by renal biopsy; the other 24 patients (48%) had no clinical signs of renal involvement. The renal biopsies were classified according to the WHO classification. Six patients had WHO class II, 12 WHO class III/IV and 8 WHO class V. <h3>Results</h3> Serum DNASE 1 levels were significantly lower in the SLE/active patient group as compared to the SLE/inactive patients (12.4 ± 3.8 vs. 16.1 ± 3.7 pg/ml, mean ± SD, p &lt; 0.005). Among the 20 SLE/inactive patients, a trend towards lower serum DNASE 1 levels was noted in patients with renal involvement (n = 9) (14.8 ± 3.6 pg/ml) as compared to patients without renal involvement (n = 11) (17.1 ± 3.5 pg/ml, p = 0.06). However, in SLE/active patients, there was no significant difference in DNASE 1 levels between patients with and without renal involvement. There was no association between the levels of DNASE 1 activity and anti-dsDNA antibody titres. Twenty-five of the patients received prednisolone treatment. Among these patients, low levels of serum DNASE 1 activity were found to be associated with high dose prednisolone therapy (r = -0.552, p &lt; 0.005). <h3>Conclusion</h3> This study demonstrated low DNASE 1 levels to be associated with high disease activity in SLE patients and may represent a novel marker of disease activity independently of anti-dsDNA antibodies. Further studies are needed to clarify the role of DNASE 1 in SLE manifestations and disease development.
Comprehensive Genetic Analysis Revealed Myeloid/Natural Killer (NK) Cell Precursor Acute Leukemia As a Novel Distinctive Leukemia Entity
Authors: Akira Nishimura, Kazuaki Yokoyama, Chika Yamagishi, Toshihiko Imamura, Takuya Naruto, Tomohiro Morio, Yukie Tanaka, Akinori Kanai, Hirotaka Matsui, Naoko Higuchi, Akiko Takada, Haruna Okuno, Shoji Saito, Shuhei Karakawa, Shogo Kobayashi, Daisuke Hasegawa, Hiroyuki Fujisaki, Daiichiro Hasegawa, Kazutoshi Koike, Takashi Koike, Shinya Rai, Katsutsugu Umeda, Hideki Sano, Yujin Sekinaka, Atsushi Ogawa, Akitoshi Kinoshita, Norio Shiba, Mizuka Miki, Fumihiko Kimura, Hideki Nakayama, Yozo Nakazawa, Takashi Taga, Tomohiko Taki, Souichi Adachi, Atsushi Manabe, Katsuyoshi Koh, Yasushi Ishida, Arinobu Tojo, Masatoshi Takagi
Journal: Blood (2020)
Secondary Hematologic Malignancies after Autologous Stem Cell Transplantation for Multiple Myeloma Are Associated with a Distinct Mutational Profile
Authors: Ariel Kleman, Arun K Singavi, Lauren Pommert, Michael T Zimmerman, Wendy Demos, Angela Mathison, Sridhar Rao, Karen-Sue Carlson, Parameswaran Hari
Journal: Blood (2020)
Interim Results of a Multicenter, Single-Arm Study to Assess Blinatumomab in Adult Patients (pts) with Minimal Residual Disease (MRD) of B-Precursor (BCP) Acute Lymphoblastic Leukemia (GMALL-MOLACT1-BLINA)
Authors: Nicola Goekbuget, Wiba Keke Wermann, Stefan Schwartz, Andreas Hüttmann, Christoph Faul, Simon Raffel, Andreas Viardot, Walter Fiedler, Nael Alakel, Matthias Stelljes, Marion Subklewe, Ralph Wäsch, Sonja Martin, Wolfram Jung, Vladan Vucinic, Mustafa Kondakci, Lars R. Fransecky, Daniela Heidenreich, Knut Wendelin, Julian Hermann, Hubert Serve, Ralf C Bargou, Max S. Topp, Monika Brüggemann
Journal: Blood (2020)
Cis-acting lnc-eRNA SEELA directly binds histone H4 to promote histone recognition and leukemia progression
Authors: Ke Fang, Wei Huang, Yu-Meng Sun, Tian-Qi Chen, Zhan-Cheng Zeng, Qian-Qian Yang, Qi Pan, Cai Han, Lin-Yu Sun, Xue-Qun Luo, Wen-Tao Wang, Yue-Qin Chen
Journal: Genome biology (2020)

Abstract Background Long noncoding enhancer RNAs (lnc-eRNAs) are a subset of stable eRNAs identified from annotated lncRNAs. They might act as enhancer activity-related therapeutic targets in cancer. However, the underlying mechanism of epigenetic activation and their function in cancer initiation and progression remain largely unknown. Results We identify a set of lncRNAs as lnc-eRNAs according to the epigenetic signatures of enhancers. We show that these lnc-eRNAs are broadly activated in MLL -rearranged leukemia ( MLL leukemia), an aggressive leukemia caused by a chromosomal translocation, through a mechanism by which the HOXA cluster initiates enhancer activity, and the epigenetic reader BRD4 cooperates with the coregulator MLL fusion oncoprotein to induce transcriptional activation. To demonstrate the functional roles of lnc-eRNAs, two newly identified lnc-eRNAs transcribed from the SEELA eRNA cluster (SEELA), SEELA1 and SEELA2, are chosen for further studies. The results show that SEELA mediated cis-activated transcription of the nearby oncogene Serine incorporate 2 ( SERINC2 ) by directly binding to the K31 amino acid (aa) of histone H4. Chromatin-bound SEELA strengthens the interaction between chromatin and histone modifiers to promote histone recognition and oncogene transcription. Further studies show that the SEELA-SERINC2 axis regulated aspects of cancer metabolism, such as sphingolipid synthesis, to affect leukemia progression. Conclusions This study shows that lnc-eRNAs are epigenetically activated by cancer-initiating oncoproteins and uncovers a cis-activating mechanism of oncogene transcription control based on lnc-eRNA-mediated epigenetic regulation of enhancer activity, providing insights into the critical roles of lnc-eRNAs in cancer initiation and progression.
International Consensus Definition of DNA Methylation Subgroups in Juvenile Myelomonocytic Leukemia
Authors: Maximilian Schönung, Julia Meyer, Peter Nöllke, Adam B. Olshen, Mark Hartmann, Norihiro Murakami, Manabu Wakamatsu, Yusuke Okuno, Christoph Plass, Mignon L. Loh, Charlotte M. Niemeyer, Hideki Muramatsu, Christian Flotho, Elliot Stieglitz, Daniel B. Lipka
Journal: Clinical Cancer Research (2020)

Known clinical and genetic markers have limitations in predicting disease course and outcome in juvenile myelomonocytic leukemia (JMML). DNA methylation patterns in JMML have correlated with outcome across multiple studies, suggesting it as a biomarker to improve patient stratification. However, standardized approaches to classify JMML on the basis of DNA methylation patterns are lacking. We, therefore, sought to define an international consensus for DNA methylation subgroups in JMML and develop classification methods for clinical implementation.
Hematopoietic Cell Transplantation for Congenital Dyserythropoietic Anemia: A Report from the Pediatric Transplant and Cellular Therapy Consortium (PTCTC)
Authors: Hemalatha G Rangarajan, Joseph R Stanek, Hisham Abdel-Azim, Arunkumar Modi, Ann Haight, Christopher M McKinney, Daniel J McKeone, David K. Buchbinder, Emmanuel Katsanis, Ghada A Abusin, Ibrahim Ahmed, Jason Law, Jorge Galvez Silva, Kanwaldeep K Mallhi, Lauri S Burroughs, Peter J Shaw, Robert Greiner, Shalini Shenoy, Michael A Pulsipher, Rolla Abu-Arja
Journal: Blood (2020)
Hypomethylating Agents in Combination with Venetoclax As a Bridge to Allogeneic Transplant in Acute Myeloid Leukemia
Authors: Vanessa E Kennedy, Gavin Hui, Daria Gaut, Varun Mittal, Caspian Oliai, Lori S. Muffly, Aaron C. Logan, Gabriel N. Mannis
Journal: Blood (2020)
Abstract 204: Modification of AIFm2 By 4HNE Leads to Retrograde Stress Signaling During Ischemia- Reperfusion Injury in Heart
Authors: Sudha Sharma, Susmita Bhattarai, Utsab Subedi, Christina Acosta, Hosne Ara, Shenuarin Bhuiyan, Manikandan Panchatcharam, Sumitra Miriyala
Journal: Circulation Research (2020)

Myocardial infarction is a leading cause of death worldwide and occurs due to blockage in blood supply to the heart. Re-establishment of blood flow after a brief period of ischemia leads to paradoxical exacerbation of the cardiomyocyte and its death. This phenomenon is known as ischemia-reperfusion injury. Major evidence in the pathogenesis of ischemia-reperfusion injury is due to oxidative stress, which is an imbalance between reactive oxygen species (ROS) and antioxidants. Membrane consisting of polyunsaturated fatty acid is attacked by ROS leading to lipid peroxidation and the generation of one of the toxic aldehydes 4-hydroxynonenal (4-HNE). Evidence suggests that 4-HNE increases during an ischemia-reperfusion injury in the heart. Apoptosis-inducing factor, mitochondrion-associated 2 (AIFM2) is a mitochondrial located oxidoreductase that participates in caspase-independent apoptosis. In this study, we sought to identify the role of 4-HNE in regulating AIFm2 translocation and cardiomyocyte death during an ischemia-reperfusion injury in the heart. Following ischemia both RNA and protein expression of AIFm2 significantly increased in the ischemic heart compared to sham. Also, 4-HNE adducted AIFm2 translocated from mitochondria to the nucleus shown by western blot analysis in ischemic heart. The mass spectrometric analysis was done to see the modification site on AIFm2 by 4-HNE and revealed that His 174 and Cys 187 are two sites on AIFm2 where 4-HNE adduction occurred. To identify the modification site responsible for AIFm2 translocation we performed site-direct mutagenesis in H9C2 cardiomyocyte, where Histidine 174 was replaced by arginine and Cys 187 was replaced by threonine. When the ischemia-reperfusion injury was induced, only Histidine 174 mutant failed to translocate to the nucleus indicating His 174 modification by 4-HNE was responsible for AIFm2 translocation. To further support the transport mechanism, protein expression of Importin; an adaptor protein responsible for the transfer of proteins to the nucleus was increased in the ischemic heart compared to sham. Collectively, those results for the first time identify the unique role of 4-HNE modification on AIFm2 protein during an ischemia-reperfusion injury in the heart.
Plasmablastic Lymphoma : 12 Year Experience from a Single Center in Colombia -South America
Authors: Paola Spirko, Leonardo José Enciso Olivera, Diana Otero, Bonell Patiño, Cristina Acon-Solano, Sebastian Alcala, Jaime Valdes, Andres Garces, Humberto Martínez Cordero, Jorge J. Castillo
Journal: Blood (2020)
Maintenance Use Is More Important Than the Choice of Bortezomib-Based Triplet Induction in Newly Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplantation
Authors: Surbhi Sidana, Shaji K. Kumar, Raphael Fraser, Noel Estrada-Merly, Maxim Norkin, Sergio Giralt, Muzaffar H. Qazilbash, Nina Shah, Anita D'Souza
Journal: Blood (2020)
Investigation of ALLO-316: A Fratricide-Resistant Allogeneic CAR T Targeting CD70 As a Potential Therapy for the Treatment of AML
Authors: Surabhi Srinivasan, Nguyen Tan, Hsin-Yuan Cheng, Yi Zhang, Silvia Tacheva-Grigorova, Tom Van Blarcom, Cesar Sommer, Duy Nguyen, Barbra Sasu, Siler Panowski
Journal: Blood (2020)
Sodium–Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Breast Cancer Among Women With Type 2 Diabetes
Authors: Melanie Suissa, Hui Yin, Oriana H.Y. Yu, Stephanie M. Wong, Laurent Azoulay
Journal: Diabetes Care (2020)

Sodium–glucose cotransporter 2 (SGLT2) inhibitors are second- to third-line antidiabetes drugs that have been shown to have cardiovascular benefits. However, in premarketing trials of the SGLT2 inhibitor dapagliflozin, there were numerical imbalances in breast cancer events compared with placebo; all occurred within 1 year of randomization (rate ratio 2.47, 95% CI 0.64–14.10) (1). In contrast, no imbalances were observed in subsequent large cardiovascular outcome trials of dapagliflozin and other SGLT2 inhibitors (2–4).

While the discrepant findings between the pre- and postmarketing trials could be due to chance, one hypothesis is that the early breast cancer imbalances are the result of an accelerated tumor-promoting effect of SGLT2 inhibitors. However, this is unlikely, given that sodium–glucose cotransporter proteins are not expressed in mammary tissue, and animal studies have failed to demonstrate that SGLT2 inhibitors have any neoplastic activity (5). Another hypothesis relates to the weight-lowering effects of SGLT2 inhibitors, which could facilitate the detection of existing breast lumps, thus leading to a transient overdetection of breast cancer. To date, this possible association has not been investigated in the real-world setting.

We conducted a population-based cohort study using the U.K. Clinical Practice Research Datalink (CPRD) (protocol: 19_272). We identified all female patients newly treated with either an SGLT2 inhibitor (dapagliflozin, …
Conversion from MRD Positive to Negative Status in AML Patients in CR1 after Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine
Authors: Arjan van de Loosdrecht, Janine van Elssen, Bjørn Tore Gjertsen, Eva Maria Wagner, Tobias Holderried, Uwe Platzbecker, Jacqueline J Cloos, Jeroen Rovers
Journal: Blood (2020)
Myocardial Tissue Characterization By T2 Mapping in Thalassemia Major
Authors: Alessia Pepe, Nicola Martini, Rita Borrello, Vincenzo Positano, Laura Pistoia, Aurelio Maggio, Giulia Guerrini, Francesco Sorrentino, Cristina Paci, Domenico Visceglie, Roberto Pedrinelli, Antonella Meloni
Journal: Blood (2020)
Clinico-Biological, Molecular and Prognostic Features of Patients with Diffuse Large B-Cell Lymphoma-Variant of Richter Syndrome: A Multicenter Retrospective Study of the French Innovative Leukemia Organization
Authors: Charline Moulin, Francis Guillemin, Thomas Remen, Florian Bouclet, Hélène Augé, Anne Quinquenel, Caroline Dartigeas, Romain Morizot, Sandra Lomazzi, Hélène Busby, Sebastien Hergalant, Eugen Tausch, Cécile Tomowiak, Veronique Leblond, Catherine Thieblemont, Florence Cymbalista, Kamel Laribi, Marie C Bene, Stephan Stilgenbauer, Romain Guieze, Pierre Feugier, Julien Broséus
Journal: Blood (2020)
Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Dose Optimization Efficacy Update and Expansion Phase Initial Results
Authors: Barbara Pro, Jonathan E. Brammer, Carla Casulo, Eric Jacobsen, Monica Mead, Neha Mehta-Shah, Jasmine M. Zain, Pier Luigi Zinzani, Stephanie Lustgarten, Hagop Youssoufian, Steven M. Horwitz
Journal: Blood (2020)
Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study
Authors: Narendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, Tamara K. Moyo, Lauren Shea, Nishitha Reddy, Julia Sheets, David M. Weiner, Praveen Ramakrishnan Geethakumari, Malathi Kandarpa, Ximena JordanBruno, Colin Thomas, Michael C. Churnetski, Andrew Hsu, Joseph Maakaron, Paolo Caimi, Pallawi Torka, Celeste Bello, Cherie Tan, Kevin A. David, Kathryn Lindsey, Irl Brian Greenwell, Murali Janakiram, Adam J Olszewski, Jonathon B. Cohen, Neil Palmisiano, Elvira Umyarova, Ryan A. Wilcox, Farrukh T Awan, Stefan K. Barta, Natalie S Grover, Nancy L. Bartlett, Yazeed Sawalha, Beth A. Christian, Alex F. Herrera, Geoffrey Shouse
Journal: Blood (2020)
Hidden in plain sight: psychological barriers to participation in lung cancer screening
Authors: Lisa Carter-Harris
Journal: Thorax (2020)

Lung cancer screening with low-dose computed tomography (LDCT) became an official recommendation in the US in 2013 in response to the scientific evidence supported by the US-based National Lung Screening Trial.1 In the years following the US implementation of lung cancer screening with LDCT, scientific evidence from subsequent international trials has supported the mortality reduction benefit of LDCT screening2 3 and is now recommended in Croatia, some regions of China and Korea, and is currently under review by the UK’s National Screening Committee. Despite the implementation of lung cancer screening, uptake remains low among screening-eligible individuals.4 Low uptake has conventionally been linked to, and supported by, evidence regarding lack of awareness, low knowledge levels and misinformation.5 6 However, as we consider the aetiology of suboptimal levels of lung cancer screening uptake and potential solutions, there are psychological consequences of lung cancer screening that are an important consideration as a potential barrier for patients who are weighing the option to screen, or not, for lung cancer.7–9 

Multiple studies have supported an increase in anxiety, depression and cancer worry among individuals who undergo lung cancer screening.7–9 Cancer …
Molecular Measurable Residual Disease Detection in Acute Myeloid Leukemia Using Error Corrected Next Generation Sequencing
Authors: Nikhil Patkar, Anam Fatima Shaikh, Chinmayee Kakirde, Rakhi Salve, Prasanna Bhanshe, Gaurav Chatterjee, Sweta Rajpal, Swapnali Joshi, Shruti Chaudhary, Rohan Kodgule, Dhanlaxmi Lalit Shetty, Hasmukh Jain, Bhausaheb Bagal, Hari Menon, Navin Khattry, Manju Sengar, Prashant Tembhare, Papagudi Ganesan Subramanian, Sumeet Gujral
Journal: Blood (2020)
Evidence of Microangiopathy in Children with Sars-Cov-2 Regardless of Clinical Presentation
Authors: Caroline Diorio, Kevin O McNerney, Michele P. Lambert, Michele Paessler, Julie Chase, Kandace Gollomp, Benjamin L Laskin, Laura A Vella, Sarah E Henrickson, Emily Liebling, Chakkapong Burudpakdee, Jessica Lee, Fran Balamuth, Allison M Blatz, Kathleen Chiotos, Julie C Fitzgerald, Therese Giglia, Audrey R Odom John, Whitney Petrosa, Kathleen Sullivan, Char M Witmer, Hamid Bassiri, Edward M Behrens, David T. Teachey
Journal: Blood (2020)
Impact of Chronic Graft-Versus-Host Disease on Non-Relapse Mortality
Authors: Justin Jiang, Qiuhong Zhao, Audrey M. Sigmund, Patrick Elder, Don M. Benson, Ashley Rosko, Maria Chaudhry, Naresh Bumma, Abdullah Khan, Srinivas Devarakonda, Sumithira Vasu, Samantha Jaglowski, Basem M. William, Alice S. Mims, Hannah Choe, Karilyn Larkin, Jonathan E. Brammer, Sarah A Wall, Nicole Grieselhuber, Ayman Saad, Sam Penza, Yvonne A. Efebera, Nidhi Sharma
Journal: Blood (2020)
Abstract PO-041: Multiplexed ion beam imaging to describe tumor-immune microenvironment and tumor heterogeneity in neuroblastoma
Authors: Marte B. Kammersgaard, Marc Bosse, Daniel Martinez, Kristopher R. Bosse, John M. Maris, Crystal L. Mackall, Robert M. Angelo, Kara L. Davis
Journal: Cancer Research (2020)

Abstract Neuroblastoma is a tumor of the peripheral sympathetic nervous system, accounting for 10% of pediatric cancer associated deaths and the most common cancer diagnosed during infancy(1,2). This neural crest derived malignancy is characterized by clinical heterogeneity ranging from spontaneous regression in some patients to treatment resistance, metastasis and death in others(3,4). Here, we report the application of Multiplexed Ion Beam Imaging (MIBI), a single-cell, high-dimensional imaging method to determine the expression and co-expression of antigens on neuroblastoma cells and describe the local immune environment. We have optimized a 40-antibody panel to capture adrenergic or mesenchymal identity(5,6), infiltrating immune cells, tissue architecture and known neuroblastoma proteins. We optimized our antibody staining and determined tissue specificity using a unique tissue microarray which included 32 NBL cores but also additional childhood solid tumors including osteosarcoma, glioblastoma, Ewing’s sarcoma, rhabdomyosarcoma, atypical teratoid rhabdoid tumor, and Wilms tumor. Healthy pediatric tissues from various organs including kidney, liver, and tonsil were also included. We have uncovered divergent neuroblastoma cell populations differentiated by co-expression of CD57, Ki67 and GPC2 as well as mesenchymal (FN1 and SNAI2/SLUG) and adrenergic (TH, GATA3 and PHOX2B) antibodies, demonstrating promising early results of our application of MIBI. We will describe infiltrating immune populations and spatial relationships to these unique tumor cell populations. Our work demonstrates the feasibility of using MIBI to make translatable discoveries in neuroblastoma and other childhood cancers. With this we will lay the foundation for future discovery and validation of novel targets for immunotherapy in neuroblastoma. Citation Format: Marte B. Kammersgaard, Marc Bosse, Daniel Martinez, Kristopher R. Bosse, John M. Maris, Crystal L. Mackall, Robert M. Angelo, Kara L. Davis. Multiplexed ion beam imaging to describe tumor-immune microenvironment and tumor heterogeneity in neuroblastoma [abstract]. In: Proceedings of the AACR Virtual Special Conference on Tumor Heterogeneity: From Single Cells to Clinical Impact; 2020 Sep 17-18. Philadelphia (PA): AACR; Cancer Res 2020;80(21 Suppl):Abstract nr PO-041.